Skip to main content
. Author manuscript; available in PMC: 2017 Jul 24.
Published in final edited form as: Mol Psychiatry. 2017 Jan 3;22(8):1172–1184. doi: 10.1038/mp.2016.229

Figure 3. Selected ESC/E(Z) gene expressions from RNAseq: ANOVAs comparing untreated and estradiol- or progesterone-treated Control and PMDD lymphoblastoid cell lines.

Figure 3

All graphs are presented as group mean ± SEM using RPKM values from RNA-sequencing. Two-way ANOVAs were performed for each gene of interest, followed by Sidak’s multiple comparisons post-hoc test in cases of a significant interaction. Untreated Control and PMDD lymphoblastoid cell lines compared with estradiol treatment (A) or progesterone treatment (B-F). (A) For JARID2 there was a significant interaction effect between diagnosis and estradiol treatment (F1,24=5.5, *p<0.05). Expression was significantly decreased after estradiol only in the PMDD group (t24=2.5, adjusted p-value<0.05). (B) For EED there was a significant interaction effect between diagnosis and progesterone treatment (F1,29=6.8, *p<0.05). Expression was significantly increased after progesterone only in the Control group (t29=2.8, adjusted p-value<0.05). (C) For EZH2 there was a significant interaction effect between diagnosis and progesterone treatment (F1,29=4.8, *p<0.05). Expression was significantly increased after progesterone only in the Control group (t29=2.4, adjusted p-value<0.05). (D) For MTF2 there was a significant interaction effect between diagnosis and progesterone treatment (F1,29=9.2, *p<0.05). Expression was significantly increased after progesterone only in the Control group (t29=2.7, adjusted p-value<0.05). Additionally, there was also a significant diagnosis effect (F1,29=5.5, *p<0.05) where MTF2 is more highly expressed in the PMDD group than the Control group (post-hoc untreated Control vs untreated PMDD t29=4.1, p<0.001). (E) For PHF19 there was a significant diagnosis effect (F1,29=16.1, *p<0.05) where expression is lower in the PMDD group compared with the Control group, but there was no interaction effect between diagnosis and progesterone treatment (F1,29=0.1, p=0.7). (E) For SIRT1 there was a significant diagnosis effect (F1,29=13.1, *p<0.05) where expression was higher in the PMDD group compared to the Control group, but there was no interaction effect between diagnosis and progesterone treatment (F1,29=0.5, p=0.5).